A carregar...
Effects of Bardoxolone Methyl on QT Interval in Healthy Volunteers
BACKGROUND: Bardoxolone methyl has been shown to increase eGFR in several clinical trials, including a phase 3 trial in patients with type 2 diabetes and stage 4 CKD (BEACON), which was terminated early due to an increase in heart failure events in bardoxolone methyl-treated patients. A separate, “t...
Na minha lista:
| Publicado no: | Cardiorenal Med |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
S. Karger AG
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6751422/ https://ncbi.nlm.nih.gov/pubmed/31158840 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000500736 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|